Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.

Current opinion in hematology - 1 Jan 2005

Goldman John

Abstract excerpt

PURPOSE OF REVIEW: The total number of leukemia cells in the body is reduced very substantially in patients with BCR-ABL-positive chronic myeloid leukemia (CML) responding to imatinib. This reduction is seen first as restoration of Ph negativity in blood and marrow and thereafter as decreasing BCR-ABL transcript levels assayed by quantitative polymerase chain reaction (PCR). Most patients with newly diagnosed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Neoplasm, Residual

Share to Piperazines

Share to Pyrimidines

Share to WT1 Proteins

Source

Identifiers

PMID: 15604889
DOI: 10.1097/01.moh.0000148551.93303.9e

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.PMID 15604889Read ↗

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.Semantic proximity Read ↗

Molecular monitoring in patients with chronic myelogenous leukemia.Semantic proximity Read ↗

Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic ResponseSemantic proximity Read ↗

Molecular monitoring in chronic myeloid leukemiaSemantic proximity Read ↗

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.Semantic proximity Read ↗

Monitoring disease response to tyrosine kinase inhibitor therapy in CML.Semantic proximity Read ↗

Chronic myeloid leukemia: molecular monitoring in clinical practice.Semantic proximity Read ↗

Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemiaSemantic proximity Read ↗

Chronic myeloid leukemia-still a few questions.Semantic proximity Read ↗

Molecular response to imatinib in late chronic-phase chronic myeloid leukemiaSemantic proximity Read ↗

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib MesylateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.